0001443669FALSE00014436692024-08-022024-08-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 2, 2024
Proto Labs, Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | |
Minnesota | | 001-35435 | | 41-1939628 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification Number) |
| | | | | | | | |
5540 Pioneer Creek Drive Maple Plain, Minnesota | | 55359 |
(Address of principal executive offices) | | (Zip Code) |
| | |
Registrant’s telephone number, including area code: | | (763) 479-3680 |
| | |
Not Applicable |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | | | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, Par Value $0.001 Per Share | PRLB | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| | | | | |
Item 2.02. | Results of Operations and Financial Condition. |
On August 2, 2024, Proto Labs, Inc. issued a press release announcing its second quarter 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
| | | | | |
Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
| | | | | |
99.1 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | |
| | Proto Labs, Inc. | |
| | | | |
| | | | |
Date: | August 2, 2024 | By: | /s/ Daniel Schumacher | |
| | | Daniel Schumacher | |
| | | Chief Financial Officer | |
Exhibit 99.1
Protolabs Reports Financial Results for the Second Quarter of 2024
Total Revenue of $126 Million
GAAP Earnings Per Share of $0.18, Non-GAAP Earnings Per Share of $0.38
MINNEAPOLIS – August 2, 2024 – Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the second quarter ended June 30, 2024.
Second Quarter 2024 Financial Highlights:
•Revenue was $125.6 million, a 2.8% increase compared to the second quarter of 2023.
•Revenue generated from Protolabs Network was $24.7 million, a 22.0% increase compared to the second quarter of 2023.
•Net income was $4.5 million, or $0.18 per diluted share, compared to net loss of $0.4 million, or $0.01 per diluted share, in the second quarter of 2023.
•Non-GAAP net income was $9.5 million, or $0.38 per diluted share, compared to $8.7 million, or $0.33 per diluted share, in the second quarter of 2023. See “Non-GAAP Financial Measures” below.
•EBITDA was $15.2 million, or 12.1% of revenue. See “Non-GAAP Financial Measures” below.
•Adjusted EBITDA was $19.3 million, or 15.4% of revenue, compared to $19.2 million, or 15.7% of revenue, in the second quarter of 2023. See “Non-GAAP Financial Measures” below.
"We executed well through the first half of 2024 despite operating in a challenging macroeconomic environment,” said Rob Bodor, President and Chief Executive Officer. "We continue to make progress on driving customer adoption of our combined offer fulfilled through both Factory and Network, while also increasing our revenue per customer. We have aligned our organization to support our initiatives, accelerate our next phase of growth, and improve our efficiency."
Dan Schumacher, Chief Financial Officer, commented, "Our results were driven by strong performance in our Network business and gross margin improvement across both Factory and Network. We remain committed to returning capital to shareholders as we repurchased $10.9 million of common stock in the quarter."
Additional Second Quarter 2024 Highlights:
•Customer contact information
◦Protolabs served 22,456 customer contacts during the quarter.
◦Revenue per customer contact increased 7.0% year-over-year to $5,595.
•Gross margin was 45.0% of revenue, compared to 43.4% of revenue in the second quarter of 2023.
•Non-GAAP gross margin was 45.7% of revenue, compared to 44.1% of revenue in the second quarter of 2023. See "Non-GAAP Financial Measures" below.
•Cash flow from operations was $14.4 million in the second quarter of 2024.
•Cash and investments balance was $112.9 million as of June 30, 2024.
Third Quarter 2024 Outlook
For the third quarter of 2024, the Company expects to generate revenue between $117 million and $125 million.
The Company expects third quarter 2024 diluted net income per share between $0.10 and $0.18, and non-GAAP diluted net income per share between $0.29 and $0.37. See "Non-GAAP Financial Measures" below.
Non-GAAP Financial Measures
The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, “non-GAAP revenue growth”). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.
The Company has included earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and costs related to the Japan closure activities (collectively, “Adjusted EBITDA”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin (“EBITDA margin”) and EBITDA margin, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency and costs related to the Japan closure activities (collectively, “Adjusted EBITDA margin”), in this press release to provide investors with additional information regarding the Company’s financial results.
The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense in this press release to provide investors with additional information regarding the Company’s financial results.
The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense and costs related to the closure of Japan (collectively, “non-GAAP operating margin”), in this press release to provide investors with additional information regarding the Company’s financial results.
The Company has included non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to the closure of Japan (collectively, “non-GAAP net income”), in this press release to provide investors with additional information regarding the Company’s financial results.
The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by service, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company’s management and board of directors to understand and evaluate operating performance and trends and provide useful measures for period-to-period comparisons of the Company’s business. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors.
Conference Call
The Company has scheduled a conference call to discuss its second quarter 2024 financial results and third quarter 2024 outlook today, August 2, 2024 at 8:30 a.m. EDT. To access the call in the U.S. please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/b94yu8yp/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.
About Protolabs
Protolabs is the fastest and most comprehensive digital manufacturing service in the world. Our digital factories produce low-volume parts in days while Protolabs Network unlocks advanced capabilities and volume pricing through its highly vetted manufacturing partners. The result? One manufacturing source—from prototyping to production—for product developers, engineers, and supply chain teams across the globe. See what's next at protolabs.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date
hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
Source: Proto Labs, Inc.
Investor Relations Contacts:
Protolabs
Ryan Johnsrud, 612-225-4873
Manager – Investor Relations and FP&A
ryan.johnsrud@protolabs.com
Gateway Group, Inc.
949-574-3860
PRLB@gateway-grp.com
Media Contact:
Protolabs
Brent Renneke, 763-479-7704
Marketing Communications Manager
brent.renneke@protolabs.com
Proto Labs, Inc.
Condensed Consolidated Balance Sheets
(In thousands)
| | | | | | | | | | | |
| | | |
| June 30, 2024 | | December 31, 2023 |
| (Unaudited) | | |
Assets | | | |
Current assets | | | |
Cash and cash equivalents | $ | 96,149 | | | $ | 83,790 | |
Short-term marketable securities | 16,792 | | | 19,013 | |
Accounts receivable, net | 70,891 | | | 72,848 | |
Inventory | 12,357 | | | 13,657 | |
Income taxes receivable | 1,400 | | | 2,228 | |
Prepaid expenses and other current assets | 10,034 | | | 9,124 | |
Total current assets | 207,623 | | | 200,660 | |
| | | |
Property and equipment, net | 243,710 | | | 253,655 | |
Goodwill | 273,991 | | | 273,991 | |
Other intangible assets, net | 23,427 | | | 25,584 | |
Long-term marketable securities | — | | | 8,019 | |
Operating lease assets | 3,790 | | | 4,628 | |
Finance lease assets | 826 | | | 960 | |
Other long-term assets | 4,839 | | | 4,856 | |
Total assets | $ | 758,206 | | | $ | 772,353 | |
| | | |
Liabilities and shareholders' equity | | | |
Current liabilities | | | |
Accounts payable | $ | 15,910 | | | $ | 15,636 | |
Accrued compensation | 15,544 | | | 15,292 | |
Accrued liabilities and other | 17,656 | | | 16,872 | |
Current operating lease liabilities | 1,534 | | | 1,585 | |
Current finance lease liabilities | 302 | | | 296 | |
| | | |
Total current liabilities | 50,946 | | | 49,681 | |
| | | |
Long-term operating lease liabilities | 2,203 | | | 3,008 | |
Long-term finance lease liabilities | 443 | | | 595 | |
Long-term deferred tax liabilities | 14,588 | | | 18,742 | |
Other long-term liabilities | 4,790 | | | 5,032 | |
| | | |
Shareholders' equity | 685,236 | | | 695,295 | |
Total liabilities and shareholders' equity | $ | 758,206 | | | $ | 772,353 | |
| | | |
| | | |
Proto Labs, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue | | | | | | | |
Injection Molding | $ | 49,080 | | | $ | 48,819 | | | $ | 101,743 | | | $ | 100,767 | |
CNC Machining | 51,239 | | | 48,297 | | | 101,171 | | | 96,401 | |
3D Printing | 21,281 | | | 21,005 | | | 42,863 | | | 42,330 | |
Sheet Metal | 3,922 | | | 3,939 | | | 7,475 | | | 8,187 | |
Other Revenue | 109 | | | 205 | | | 269 | | | 439 | |
Total Revenue | 125,631 | | | 122,265 | | | 253,521 | | | 248,124 | |
| | | | | | | |
Cost of revenue | 69,085 | | | 69,142 | | | 139,508 | | | 141,225 | |
Gross profit | 56,546 | | | 53,123 | | | 114,013 | | | 106,899 | |
| | | | | | | |
Operating expenses | | | | | | | |
Marketing and sales | 23,291 | | | 21,730 | | | 46,451 | | | 44,181 | |
Research and development | 10,661 | | | 9,865 | | | 21,828 | | | 20,542 | |
General and administrative | 16,595 | | | 15,822 | | | 32,908 | | | 32,655 | |
Closure of Japan business | — | | | 98 | | | — | | | 164 | |
Total operating expenses | 50,547 | | | 47,515 | | | 101,187 | | | 97,542 | |
Income from operations | 5,999 | | | 5,608 | | | 12,826 | | | 9,357 | |
Other income (loss), net | 1,361 | | | (3,368) | | | 2,260 | | | (2,078) | |
Income before income taxes | 7,360 | | | 2,240 | | | 15,086 | | | 7,279 | |
Provision for income taxes | 2,820 | | | 2,623 | | | 5,278 | | | 5,003 | |
Net income (loss) | $ | 4,540 | | | $ | (383) | | | $ | 9,808 | | | $ | 2,276 | |
| | | | | | | |
Net income (loss) per share: | | | | | | | |
Basic | $ | 0.18 | | | $ | (0.01) | | | $ | 0.39 | | | $ | 0.09 | |
Diluted | $ | 0.18 | | | $ | (0.01) | | | $ | 0.38 | | | $ | 0.09 | |
| | | | | | | |
Shares used to compute net income (loss) per share: | | | | | | | |
Basic | 25,313,036 | | 26,210,478 | | 25,473,937 | | 26,414,467 |
Diluted | 25,372,972 | | 26,210,478 | | 25,573,344 | | 26,445,427 |
| | | | | | | |
Proto Labs, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| | | | | | | | | | | |
| | | |
| Six Months Ended June 30, |
| 2024 | | 2023 |
Operating activities | | | |
Net income | $ | 9,808 | | | $ | 2,276 | |
Adjustments to reconcile net income to net cash provided by operating activities: | | | |
Depreciation and amortization | 18,075 | | | 18,883 | |
Stock-based compensation expense | 8,520 | | | 7,370 | |
Deferred taxes | (4,144) | | | (5,605) | |
Interest on finance lease obligations | 18 | | | 568 | |
Loss on foreign currency translation | — | | | 3,906 | |
Gain on disposal of property and equipment | (20) | | | (428) | |
Other | 64 | | | 215 | |
Changes in operating assets and liabilities | 3,460 | | | 4,682 | |
Net cash provided by operating activities | 35,781 | | | 31,867 | |
| | | |
Investing activities | | | |
Purchases of property, equipment and other capital assets | (6,784) | | | (6,829) | |
Proceeds from sales of property, equipment and other capital assets | 30 | | | 623 | |
| | | |
| | | |
| | | |
Proceeds from call redemptions and maturities of marketable securities | 10,419 | | | 14,020 | |
Net cash provided by investing activities | 3,665 | | | 7,814 | |
| | | |
Financing activities | | | |
Proceeds from exercises of stock options | 2,094 | | | 1,986 | |
Purchases of shares withheld for tax obligations | (1,920) | | | (1,425) | |
Repurchases of common stock | (26,940) | | | (30,064) | |
Principal repayments of finance lease obligations | (146) | | | (163) | |
Net cash used in financing activities | (26,912) | | | (29,666) | |
Effect of exchange rate changes on cash and cash equivalents | (175) | | | (80) | |
Net increase in cash and cash equivalents | 12,359 | | | 9,935 | |
Cash and cash equivalents, beginning of period | 83,790 | | | 56,558 | |
Cash and cash equivalents, end of period | $ | 96,149 | | | $ | 66,493 | |
| | | |
Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Net Income (Loss) per Share
(In thousands, except share and per share amounts)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities | | | | | | | |
GAAP net income (loss) | $ | 4,540 | | | $ | (383) | | | $ | 9,808 | | | $ | 2,276 | |
Add back: | | | | | | | |
Stock-based compensation expense | 4,244 | | | 3,675 | | | 8,520 | | | 7,370 | |
Amortization expense | 921 | | | 1,484 | | | 1,908 | | | 3,010 | |
Unrealized (gain) loss on foreign currency | (88) | | | 187 | | | 149 | | | 115 | |
Costs related to Japan closure activities | — | | | 4,004 | | | — | | | 4,070 | |
Total adjustments 1 | 5,077 | | | 9,350 | | | 10,577 | | | 14,565 | |
Income tax benefits on adjustments 2 | (85) | | | (296) | | | (439) | | | (298) | |
Non-GAAP net income | $ | 9,532 | | | $ | 8,671 | | | $ | 19,946 | | | $ | 16,543 | |
| | | | | | | |
| | | | | | | |
Non-GAAP net income per share: | | | | | | | |
Basic | $ | 0.38 | | | $ | 0.33 | | | $ | 0.78 | | | $ | 0.63 | |
Diluted | $ | 0.38 | | | $ | 0.33 | | | $ | 0.78 | | | $ | 0.63 | |
| | | | | | | |
Shares used to compute non-GAAP net income per share: | | | | | | | |
Basic | 25,313,036 | | 26,210,478 | | 25,473,937 | | 26,414,467 |
Diluted | 25,372,972 | | 26,224,562 | | 25,573,344 | | 26,445,427 |
| | | | | | | |
1Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency and costs related to Japan closure activities were included in the following GAAP consolidated statement of operations categories:
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
| | | | | | | |
Cost of revenue | $ | 810 | | | $ | 803 | | | $ | 1,611 | | | $ | 1,611 | |
| | | | | | | |
Marketing and sales | 819 | | | 855 | | | 1,652 | | | 1,547 | |
Research and development | 667 | | | 641 | | | 1,359 | | | 1,212 | |
General and administrative | 2,869 | | | 2,861 | | | 5,806 | | | 6,010 | |
Closure of Japan business | — | | | 98 | | | — | | | 164 | |
Total operating expenses | 4,355 | | | 4,455 | | | 8,817 | | | 8,933 | |
| | | | | | | |
Other income (loss), net | (88) | | | 4,092 | | | 149 | | | 4,021 | |
Total adjustments | $ | 5,077 | | | $ | 9,350 | | | $ | 10,577 | | | $ | 14,565 | |
| | | | | | | |
2For the three and six months ended June 30, 2024 and 2023, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the quarter.
Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Gross Margin
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue | $ | 125,631 | | | $ | 122,265 | | | $ | 253,521 | | | $ | 248,124 | |
Gross profit | 56,546 | | | 53,123 | | | 114,013 | | | 106,899 | |
GAAP gross margin | 45.0 | % | | 43.4 | % | | 45.0 | % | | 43.1 | % |
Add back: | | | | | | | |
Stock-based compensation expense | 468 | | | 461 | | | 927 | | | 927 | |
Amortization expense | 342 | | | 342 | | | 684 | | | 684 | |
Total adjustments | 810 | | | 803 | | | 1,611 | | | 1,611 | |
Non-GAAP gross profit | $ | 57,356 | | | $ | 53,926 | | | $ | 115,624 | | | $ | 108,510 | |
Non-GAAP gross margin | 45.7 | % | | 44.1 | % | | 45.6 | % | | 43.7 | % |
| | | | | | | |
Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Operating Margin
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue | $ | 125,631 | | | $ | 122,265 | | | $ | 253,521 | | | $ | 248,124 | |
Income from operations | 5,999 | | | 5,608 | | | 12,826 | | | 9,357 | |
GAAP operating margin | 4.8 | % | | 4.6 | % | | 5.1 | % | | 3.8 | % |
Add back: | | | | | | | |
Stock-based compensation expense | 4,244 | | | 3,675 | | | 8,520 | | | 7,370 | |
Amortization expense | 921 | | | 1,484 | | | 1,908 | | | 3,010 | |
Costs related to Japan closure activities | — | | | 98 | | | — | | | 164 | |
Total adjustments | 5,165 | | | 5,257 | | | 10,428 | | | 10,544 | |
Non-GAAP income from operations | $ | 11,164 | | | $ | 10,865 | | | $ | 23,254 | | | $ | 19,901 | |
Non-GAAP operating margin | 8.9 | % | | 8.9 | % | | 9.2 | % | | 8.0 | % |
| | | | | | | |
Proto Labs, Inc.
Reconciliation of GAAP Net Income (Loss) to EBITDA and Adjusted EBITDA
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Revenue | $ | 125,631 | | | $ | 122,265 | | | $ | 253,521 | | | $ | 248,124 | |
GAAP net income (loss) | 4,540 | | | (383) | | | 9,808 | | | 2,276 | |
GAAP net income (loss) margin | 3.6 | % | | (0.3 | %) | | 3.9 | % | | 0.9 | % |
Add back: | | | | | | | |
Amortization expense | $ | 921 | | | $ | 1,484 | | | $ | 1,908 | | | $ | 3,010 | |
Depreciation expense | 8,051 | | | 8,011 | | | 16,167 | | | 15,873 | |
Interest income, net | (1,149) | | | (372) | | | (2,261) | | | (722) | |
Provision for income taxes | 2,820 | | | 2,623 | | | 5,278 | | | 5,003 | |
EBITDA | 15,183 | | | 11,363 | | | 30,900 | | | 25,440 | |
EBITDA Margin | 12.1 | % | | 9.3 | % | | 12.2 | % | | 10.3 | % |
Add back: | | | | | | | |
Stock-based compensation expense | 4,244 | | | 3,675 | | | 8,520 | | | 7,370 | |
Unrealized (gain) loss on foreign currency | (88) | | | 187 | | | 149 | | | 115 | |
Costs related to Japan closure activities | — | | | 4,004 | | | — | | | 4,070 | |
Total adjustments | 4,156 | | | 7,866 | | | 8,669 | | | 11,555 | |
Adjusted EBITDA | $ | 19,339 | | | $ | 19,229 | | | $ | 39,569 | | | $ | 36,995 | |
Adjusted EBITDA Margin | 15.4 | % | | 15.7 | % | | 15.6 | % | | 14.9 | % |
| | | | | | | |
Proto Labs, Inc.
Comparison of GAAP to Non-GAAP Revenue Growth by Region
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | |
| Three Months Ended June 30, 2024 | | Three Months Ended June 30, 2023 | | % Change2 | | % Change Organic3 |
| GAAP | | Foreign Currency1 | | Non-GAAP | | GAAP | | |
Revenues | | | | | | | | | | | |
United States | $ | 98,541 | | | $ | — | | | $ | 98,541 | | | $ | 96,321 | | | 2.3 | % | | 2.3 | % |
Europe | 27,090 | | | 24 | | | 27,114 | | | 25,944 | | | 4.4 | % | | 4.5 | % |
Total revenue | $ | 125,631 | | | $ | 24 | | | $ | 125,655 | | | $ | 122,265 | | | 2.8 | % | | 2.8 | % |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Six Months Ended June 30, 2024 | | Six Months Ended June 30, 2023 | | % Change2 | | % Change Organic3 |
| GAAP | | Foreign Currency1 | | Non-GAAP | | GAAP | | |
Revenues | | | | | | | | | | | |
United States | $ | 200,022 | | | $ | — | | | $ | 200,022 | | | $ | 194,067 | | | 3.1 | % | | 3.1 | % |
Europe | 53,499 | | | (883) | | | 52,616 | | | 54,057 | | | (1.0 | %) | | (2.7 | %) |
Total revenue | $ | 253,521 | | | $ | (883) | | | $ | 252,638 | | | $ | 248,124 | | | 2.2 | % | | 1.8 | % |
| | | | | | | | | | | |
1Revenue for the three and six months ended June 30, 2024 has been recalculated using 2023 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
2This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2023 to GAAP revenue for the three and six months ended June 30, 2024.
3This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2023 to non-GAAP revenue for the three and six months ended June 30, 2024 (as recalculated using the foreign currency exchange rates in effect during the three and six months ended June 30, 2023) in order to provide a constant-currency comparison.
Proto Labs, Inc.
Comparison of GAAP to Non-GAAP Revenue Growth by Service Line
(In thousands)
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | |
| Three Months Ended June 30, 2024 | | Three Months Ended June 30, 2023 | | % Change2 | | % Change Organic3 |
| GAAP | | Foreign Currency1 | | Non-GAAP | | GAAP | | |
Revenues | | | | | | | | | | | |
Injection Molding | $ | 49,080 | | | $ | (60) | | | $ | 49,020 | | | $ | 48,819 | | | 0.5 | % | | 0.4 | % |
CNC Machining | 51,239 | | | 90 | | | 51,329 | | | 48,297 | | | 6.1 | | | 6.3 | |
3D Printing | 21,281 | | | (20) | | | 21,261 | | | 21,005 | | | 1.3 | | | 1.2 | |
Sheet Metal | 3,922 | | | 17 | | | 3,939 | | | 3,939 | | | (0.4) | | | — | |
Other Revenue | 109 | | | (3) | | | 106 | | | 205 | | | (46.8) | | | (48.3) | |
Total Revenue | $ | 125,631 | | | $ | 24 | | | $ | 125,655 | | | $ | 122,265 | | | 2.8 | % | | 2.8 | % |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Six Months Ended June 30, 2024 | | Six Months Ended June 30, 2023 | | % Change2 | | % Change Organic3 |
| GAAP | | Foreign Currency1 | | Non-GAAP | | GAAP | | |
Revenues | | | | | | | | | | | |
Injection Molding | $ | 101,743 | | | $ | (468) | | | $ | 101,275 | | | $ | 100,767 | | | 1.0 | % | | 0.5 | % |
CNC Machining | 101,171 | | | (218) | | | 100,953 | | | 96,401 | | | 4.9 | | | 4.7 | |
3D Printing | 42,863 | | | (207) | | | 42,656 | | | 42,330 | | | 1.3 | | | 0.8 | |
Sheet Metal | 7,475 | | | 13 | | | 7,488 | | | 8,187 | | | (8.7) | | | (8.5) | |
Other Revenue | 269 | | | (3) | | | 266 | | | 439 | | | (38.7) | | | (39.4) | |
Total Revenue | $ | 253,521 | | | $ | (883) | | | $ | 252,638 | | | $ | 248,124 | | | 2.2 | % | | 1.8 | % |
| | | | | | | | | | | |
1Revenue for the three and six months ended June 30, 2024 has been recalculated using 2023 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.
2This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2023 to GAAP revenue for the three and six months ended June 30, 2024.
3This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2023 to non-GAAP revenue for the three and six months ended June 30, 2024 (as recalculated using the foreign currency exchange rates in effect during the three and six months ended June 30, 2023) in order to provide a constant-currency comparison.
Proto Labs, Inc.
Customer Contact Information
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2024 | | 2023 | | 2024 | | 2023 |
Customer contacts | 22,456 | | 23,377 | | 34,338 | | 35,743 |
Revenue per customer contact | $ | 5,595 | | | $ | 5,230 | | | $ | 7,383 | | | $ | 6,942 | |
| | | | | | | |
Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Guidance
(In thousands, except per share and per share amounts)
(Unaudited)
| | | | | | | | | | | |
| | | |
| Q3 2024 Outlook |
| Low | | High |
GAAP diluted net income per share | $ | 0.10 | | | $ | 0.18 | |
Add back: | | | |
Stock-based compensation expense | 0.16 | | | 0.16 | |
Amortization expense | 0.03 | | | 0.03 | |
Unrealized (gain) loss on foreign currency | 0.00 | | | 0.00 | |
Total adjustments | 0.19 | | | 0.19 | |
Non-GAAP diluted net income per share | $ | 0.29 | | | $ | 0.37 | |
| | | |
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Proto Labs (NYSE:PRLB)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Proto Labs (NYSE:PRLB)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024